Peanut allergy is defined as a harmful health effect resulting from a specific and reproducible immune response following the ingestion of peanuts. While exposure to dietary antigens within the gastro-intestinal tract normally leads to oral tolerance, in certain individuals this mechanism fails. This results in sensitization and subsequent allergic responses towards innocuous food antigens. The most dangerous of these responses is an acute systemic reaction called anaphylaxis.
Peanut allergy has prevalence of 1–2.5% in developed nations and a low rate of remission-only around 20% in children. Though the specific etiology of peanut allergy is unclear, it is likely due to the interaction of genetic predisposition with environmental factors . Currently the only available strategy for managing peanut allergy long-term is avoidance and the treatment of acute reactions with injectable epinephrine. Some physicians have begun to offer their patients an investigational treatment known as experimental peanut oral immunotherapy. Though these grassroots efforts can be effective in desensitizing patients to peanut, they lack standardization and regulatory agency approval, thus making it difficult to ensure the safety of the treatment. With a complete absence of approved therapies available, peanut allergy is an indication with extremely high unmet need.
GlobalData projects the global peanut allergy marketplace — which, for the purposes of this report, comprises eight major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Canada, and Australia) — to experience intense growth during the forecast period. GlobalData forecasts the peanut allergy market to grow over 1,700-fold between 2017 and 2027. This incredible growth stems from the projected entry of four new peanut immunotherapy products into a previously empty marketplace. These new therapies include three oral immunotherapy (OIT) products-Aimmune Therapeutics’ AR-101, Prota Therapeutics’ PPOIT, and Camallergy’s CA-002-and one epicutaneous immunotherapy product-DBV Technologies’ Viaskin Peanut.
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2332314
Growing at a compound annual growth rate (CAGR) of 111% over the 10-year forecast period, in 2027 peanut allergy sales are projected to reach over $4.5 billion. The majority of sales (88%) will come from the US. This is mainly due to the US having a large population of potential patients (estimated 3,000,000 probable diagnosed prevalent cases), an elevated expected price tag for new therapies (nearly 5–7 times that of the other geographies), and a higher expected treatment rate (based on good accessibility to allergy specialists).
Aimmune’s AR-101, is expected to be the market leader among the four peanut immunotherapy products released during the forecast, period, capturing over 67% of the peanut allergy market in 2027, worth an estimated $3.0B. Second in sales is DBV Technologies’ Viaskin Peanut, which is projected to capture 32% of the peanut allergy market in 2027, totaling nearly $1.4B in sales. Finally, sales for Prota Therapeutics’ and Camallergy’s products, PPOIT and CA-002, together are only expected to total 1%. This estimate is based on GlobalData’s assumption that within the forecast period these therapies will each only be released in one geography-Australia and the 5EU respectively.
Key Questions Answered:
— The projected entry of four new peanut immunotherapy products during the forecast period is expected to spur intense growth within the peanut allergy market. How are these immunotherapy products similar and different? What are the strengths and weaknesses of the small biotech and start-up companies launching these therapies? Which of these drugs will have the highest peak sales, and why?
— Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are considerably high unmet needs within the peanut allergy indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?
— The peanut allergy market is likely to remain a dynamic, growing space throughout the forecast period and beyond. What are the main R&D trends in this market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early stage clinical development?
Scope:
- Overview of peanut allergy including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
— Annualized peanut allergy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
— Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the peanut allergy therapeutics market.
— Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
— Analysis of the current and future market competition in the global peanut allergy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2332314
Reasons to buy:
The report will enable you to —
— Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
— Develop business strategies by understanding the trends shaping and driving the global peanut allergy therapeutics market.
— Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global peanut allergy therapeutics market in future.
— Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
— Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
— Track drug sales in the global peanut allergy therapeutics market from 2017–2027.
— Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Players:
Aimmune Therapeutics
DBV Technologies
Prota Therapeutics
Cambridge Allergy
Sanofi
Regeneron
AnaptysBio
Mylan
ALK Abello
Stallargenes Greer
Astellas Pharma
Immunomic Therapeutics
HAL Allergy
Aravax
Immune Design
ASIT Biotech
Allakos
BioLingus
Allergy Therapeutics
Sementis
Selecta Biosciences
Intrommune Therapeutics
Adverum Biotechnologies
Virtici
Alfacyte
Perosphere
Get More Access with Full TOC@ http://www.orbisresearch.com/reports/index/peanut-allergy-opportunity-analysis-and-forecasts-to-2027
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Hector Costello
Senior Manager — Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas — 75204, U.S.A.
Phone No.: +1 (214) 884–6817; +912064101019
Email id: [email protected]
